Clinical Trial

Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults

Study acronym: PREVENTABLE
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.
Protocol Amendment History 16 amendments
This ClinicalTrials.gov record has been amended 16 times since 2020-02-07; most recent amendment 2026-06-02.
Status change: Not Yet Recruiting → Recruiting 2020-09-10
Trial Details
NCT Number NCT04262206
Lead Sponsor Duke University
Collaborators: National Institute on Aging (NIA), National Heart, Lung, and Blood Institute (NHLBI), Wake Forest University Health Sciences
Conditions Cognitive Impairment, Mild, Dementia, Cardiovascular Diseases
Enrollment 20,000 participants
Start Date 2020-09-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-04